CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, ...

My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left without hope.” ...

The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

The U.S. Food and Drug Administration (FDA ... Concurrently, AstraZeneca's Calquence (acalabrutinib) in combination with bendamustine and rituximab was recommended for approval in the European ...

Under the terms of the agreement, Eagle will receive $69 million before transaction costs as an upfront payment in exchange for a prespecified amount of Eagle’s royalty interest for net sales of ...

AstraZeneca announced on Monday that it secured a US regulatory approval and a positive EU recommendation for two of its ...

Acute myelogenous leukemia (AML) is seen in this stock image. Duke researchers have discovered a new combination of drugs that is more effective than chemotherapy at killing acute myeloid leukemia ...

Roche/AbbVie’s cancer drug venetoclax, which is set to become ... compared with standard bendamustine and Rituxan therapy. Results of MURANO published last week will form the basis of a ...

During a Case-Based Roundtable® event, John N. Allan, MD, discussed how new regimens using BTK inhibitors and venetoclax ...